Pharmacy · Independent exam preparation
PTCE Preparation: Medication Decisions, Federal Rules, Safety, and Calculations Study Guide
Practise medication recognition, federal dispensing rules, error prevention, and pharmacy calculations through 60 focused concepts and original PTCE learning drills.
By CertMedbry · Updated 30 October 2026
Recognise duplicate therapy, distinguish serious medication warnings, apply federal controlled-substance rules, and calculate accurate quantities and days supplies. This guide prepares candidates for PTCB's Pharmacy Technician Certification Examination using the outline effective January 6, 2026. Its 60 concepts selectively develop practical decisions across all four domains; the official outline remains the full examination scope. The accompanying questions and flashcards are independent learning materials.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide cover?
It covers the Pharmacy Technician Certification Examination, or PTCE, administered by the Pharmacy Technician Certification Board. Passing the PTCE is part of PTCB's CPhT certification pathway. NHA's ExCPT is a separate examination, despite sharing the CPhT credential designation; its domains and item allocations do not govern this guide.
Certified Pharmacy Technician (CPhT) — PTCB · NHA Certified Pharmacy Technician (CPhT): Test Plan for the ExCPT Exam
How many questions are scored, and how long is the examination?
PTCB's credential information identifies 90 multiple-choice questions: 80 scored questions and 10 unscored questions. Examination time is 110 minutes. The total testing allocation is two hours, including the tutorial and survey.
What delivery method, adaptivity, and item styles are established?
The PTCE is a computer-based, multiple-choice examination administered in person at Pearson test centers. The cited PTCB information does not establish whether the examination uses an adaptive testing algorithm. The 20 questions here are four-option, single-best-answer learning drills.
Certified Pharmacy Technician (CPhT) — PTCB · PTCE Content Outline — Effective January 6, 2026
Which outline version and effective date apply?
The controlling document is PTCE Content Outline v1.4, whose footer is dated August 2024 and whose effective date is January 6, 2026. The effective date determines applicability. An older outline assigning 40% to Medications does not govern this guide.
How is examination content weighted?
The official weights are Medications 35%; Federal Requirements 18.75%; Patient Safety and Quality Assurance 23.75%; and Order Entry and Processing 22.50%. This guide allocates 21, 11, 14, and 14 concepts respectively. Questions and flashcards each allocate 7, 4, 5, and 4 items, approximating those weights within a small set.
Do these 60 concepts cover the entire official scope?
No. They provide a selective foundation across every official domain. Use the complete outline to extend study into additional medications, controlled-prescription transfers, pseudoephedrine processing, product-specific stability, administration supplies, and other listed knowledge areas. These original learning materials are not official PTCB questions and do not predict a passing result.
How should legal and medication references be applied?
Federal legal examples use the cited DEA and FDA materials, with DEA manuals identified by their publication editions rather than treated as new publications. State requirements may be stricter. Medication handling examples apply to the cited product labels; a different formulation or manufacturer may require different instructions. Calculation cases supply assumed, verified orders rather than prescribing recommendations.
DEA Pharmacist's Manual — 2022 Edition · DailyMed — AMOXIL Oral Suspension · PTCE Content Outline — Effective January 6, 2026
This guide follows PTCB's PTCE pathway to the Certified Pharmacy Technician credential. NHA's ExCPT also leads to a CPhT designation but is a separate examination with a different blueprint. Federal examples address U.S. requirements; state law and authorised technician duties may impose additional conditions.
Outline used: PTCE Content Outline v1.4, dated August 2024, effective January 6, 2026; verified for the October 11, 2026 reference date. The workbook label 'Certified Pharmacy Technician' names the CPhT credential. PTCB's official credential page explicitly associates that credential with the PTCE, which is the examination used for this set. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Medications35%
1.Which generic medication is supplied as Zoloft?
Zoloft contains sertraline, a selective serotonin reuptake inhibitor. Recognising a brand–generic pair links a prescription, patient history, and stock product to the same active ingredient. The class describes its pharmacologic group, but class membership alone does not establish interchangeability. For product selection, match the ingredient, strength, dosage form, and prescribed directions. A different SSRI is a different medication even when its indication overlaps with sertraline.
Apply it
A patient reports taking Zoloft while a new prescription lists sertraline. Identify the shared active ingredient and flag the possible duplicate entry before another supply is processed under a second medication name.
Common pitfall: Fluoxetine and paroxetine are also SSRIs, but belonging to the same class does not make either the generic name of Zoloft.
2.How does atorvastatin lower cholesterol?
Atorvastatin, supplied under the Lipitor brand, inhibits HMG-CoA reductase, an enzyme involved in cholesterol synthesis. Reduced hepatic cholesterol synthesis promotes removal of LDL cholesterol from circulation. This mechanism identifies atorvastatin as a statin and helps connect its lipid-lowering indication with its class. It does not identify atorvastatin as an immediate treatment for chest discomfort. Medication recognition should connect ingredient, class, and purpose rather than rely on a brand name alone.
Apply it
During profile entry, a patient describes Lipitor as a cholesterol medicine. Record atorvastatin as the ingredient and recognise the statin classification, while keeping any new report of chest discomfort separate from its chronic treatment purpose.
Common pitfall: A cardiovascular indication does not mean every cardiovascular drug treats an acute symptom; lipid modification and rapid relief of angina involve different mechanisms.
3.How can different names conceal duplicate atorvastatin therapy?
Brand and generic names can describe the same active ingredient. Lipitor and atorvastatin therefore require an ingredient-level comparison when both appear on a medication list. Two entries may represent a replacement prescription, an outdated record, or unintended concurrent use; the names alone do not resolve intent. Identify the overlap and obtain pharmacist review before processing a second therapy as though it were unrelated. Strength differences do not eliminate duplication.
Apply it
A profile contains active Lipitor 20 mg daily and a newly received atorvastatin 40 mg daily order. Flag the common ingredient and possible dose change so the pharmacist can establish which instruction is current.
Common pitfall: Different tablet strengths can indicate a planned change, but they do not justify assuming both prescriptions should remain active and be taken together.
DailyMed — LIPITOR · PTCE Content Outline — Effective January 6, 2026
4.What separates therapeutic duplication from identical ingredients?
Therapeutic duplication can involve the same ingredient or different medications with substantially overlapping therapeutic actions. Ingredient matching identifies exact duplication; class and indication comparisons identify broader overlap. Two SSRIs, for example, warrant review even though their generic names differ. The important decision is whether the combination has an intentional treatment rationale, such as a supervised transition. A technician recognises the pattern and preserves the information needed for pharmacist assessment rather than independently cancelling treatment.
Apply it
A patient collecting sertraline says an older fluoxetine prescription is still being taken every morning. Document both names and the reported concurrent use, then bring the overlap to the pharmacist before completing the transaction.
Common pitfall: Different generic names do not exclude therapeutic duplication, and overlapping classes do not by themselves prove that a documented, supervised transition is erroneous.
FDA — Depression Medicines · PTCE Content Outline — Effective January 6, 2026
5.Why can grapefruit increase atorvastatin toxicity risk?
Grapefruit juice can inhibit intestinal CYP3A4 activity, increasing exposure to atorvastatin. Higher exposure can increase the risk of muscle toxicity rather than improve treatment predictably. The Lipitor label specifically warns about excessive grapefruit juice consumption. The discriminating cue is an exposure-increasing food interaction, not reduced absorption. Collect the amount and frequency of consumption and route the concern to the pharmacist; do not invent a universal safe quantity for every patient or statin.
Apply it
A patient taking atorvastatin reports beginning a daily routine of several large glasses of grapefruit juice. Record that sustained intake and alert the pharmacist because the food may increase medication exposure and muscle-related risk.
Common pitfall: Do not treat grapefruit as a class-wide interaction of identical magnitude for every statin, or describe this interaction as making atorvastatin less effective.
6.Which atorvastatin symptoms suggest a serious muscle reaction?
Atorvastatin can cause myopathy and, rarely, rhabdomyolysis. Unexplained muscle pain, tenderness, or weakness is particularly concerning when accompanied by malaise or fever. Rhabdomyolysis involves muscle breakdown and can produce kidney injury. These clues distinguish a potentially serious adverse effect from an isolated administrative question about the prescription. A technician should promptly bring the symptom report to the pharmacist and capture relevant medication changes rather than reassure the patient that all muscle symptoms are expected.
Apply it
While requesting a refill, a patient reports new unexplained thigh weakness and fever after a recent medication change. Preserve the symptom details and obtain prompt pharmacist assessment instead of handling the call solely as a refill request.
Common pitfall: A familiar medication taken for months can still be implicated after an interacting drug or dose change; duration of prior use does not exclude toxicity.
7.Why are nitroglycerin and sildenafil contraindicated together?
Nitroglycerin increases nitric-oxide-mediated cyclic GMP signalling, which relaxes vascular smooth muscle. Sildenafil inhibits phosphodiesterase type 5, reducing cyclic GMP breakdown. Their combined effects can cause severe hypotension, syncope, or myocardial ischemia. The Nitrostat label contraindicates use with PDE-5 inhibitors. A sildenafil entry is therefore a specific interaction signal requiring pharmacist assessment, even when the medications serve different conditions. Do not independently supply a timing workaround from incomplete information.
Apply it
A Nitrostat prescription arrives for a patient whose profile includes sildenafil. Pause routine processing and provide the pharmacist with both medication names and the patient's reported use so the contraindicated combination can be assessed.
Common pitfall: Different indications do not prevent an interaction; the danger arises from converging vascular signalling effects rather than from treating the same disease twice.
8.How does sublingual Nitrostat administration differ from swallowing?
Nitrostat tablets are intended to dissolve under the tongue or in the buccal pouch. Absorption through oral mucosa supports their intended rapid action for angina. Swallowing a tablet as an ordinary oral medication changes the administration pathway and does not follow the product instructions. The dosage form and route must remain explicit during order entry and labelling. Instructions about repeat doses and emergency care must follow the verified prescription and product guidance rather than an improvised technician explanation.
Apply it
A draft label for Nitrostat reads 'swallow one tablet.' Compare it with the sublingual product and original order, then stop the label for correction and pharmacist verification before the medication reaches the patient.
Common pitfall: A tablet's appearance does not establish that it should be swallowed; sublingual and buccal administration instructions are essential parts of the product's use.
9.Why should Nitrostat remain in its original container?
The Nitrostat label directs storage in its original glass container with the cap tightly closed to prevent loss of potency. Packaging is therefore part of medication stability rather than simply a convenience. A routine transfer into a weekly organiser would remove the tablets from the labelled protective system. Identify original-container instructions before repackaging or selecting adherence aids, and preserve the manufacturer's storage protection when preparing the product for dispensing.
Apply it
A caregiver asks staff to place every medication into a weekly organiser, including Nitrostat. Identify its original-glass-container instruction and involve the pharmacist in arranging an adherence plan that preserves the tablet's labelled storage conditions.
Common pitfall: Do not apply a single repackaging method to all tablets; a solid dosage form can still depend on its original container for stability.
10.Which condition is metformin extended release intended to treat?
Metformin extended-release tablets are used with diet and exercise to improve glycemic control in type 2 diabetes. Metformin reduces hepatic glucose production and improves insulin sensitivity, linking its indication to glucose regulation. The extended-release designation describes drug delivery over time, not a different disease indication. Recognising the indication supports accurate profile review, but it does not authorise a technician to determine whether a patient's renal function, acute illness, or treatment goals make therapy appropriate.
Apply it
A patient describes metformin extended release as a medication for type 2 diabetes. Link that purpose to the correct product while separately recording a new concern about kidney function for the pharmacist's assessment.
Common pitfall: A correct indication does not establish that the medication is suitable under every current clinical condition, and extended release does not remove metformin's important warnings.
11.How should the cited metformin extended-release tablets be handled?
The cited metformin extended-release label directs patients to swallow tablets whole and not crush, cut, or chew them. Altering the tablet can interfere with the intended release characteristics. The label also directs administration with the evening meal. Match instructions to the actual extended-release product rather than transferring directions from another formulation. Difficulty swallowing is a reason to obtain pharmacist review of suitable alternatives, not permission to change the dosage form independently.
Apply it
A caregiver proposes crushing a patient's metformin extended-release tablet into applesauce. Identify the swallow-whole instruction and bring the swallowing difficulty to the pharmacist so an appropriate formulation plan can be established before administration.
Common pitfall: A familiar generic ingredient does not make immediate-release and extended-release administration interchangeable; the release designation changes handling decisions even when the ingredient is identical.
12.Why is renal impairment important with metformin?
Metformin carries a warning for potentially fatal lactic acidosis. Renal impairment can reduce drug elimination and increase accumulation. Concerning symptoms include malaise, muscle pain, respiratory distress, unusual somnolence, and abdominal symptoms. Suspected metformin-associated lactic acidosis requires urgent medical evaluation. The label calls for immediate discontinuation of metformin and prompt supportive measures in a hospital setting. A technician recognises the emergency warning pattern, immediately involves the pharmacist, and activates the appropriate urgent-response pathway without delaying medical care; diagnosis and treatment belong to the clinical team.
Apply it
A metformin patient reports worsening kidney function, unusual weakness, and shortness of breath. Immediately involve the pharmacist and activate the urgent-response pathway for emergency medical evaluation. Do not place the patient in a routine callback queue or wait for laboratory confirmation before arranging urgent care.
Common pitfall: Do not dismiss systemic symptoms as ordinary gastrointestinal intolerance or let pharmacist consultation delay emergency medical evaluation. Recognising a warning pattern does not require independently diagnosing lactic acidosis or directing its treatment.
13.How does albuterol relieve bronchospasm?
Albuterol is a short-acting beta-2 adrenergic agonist that relaxes bronchial smooth muscle. Its HFA inhalation product is indicated for treatment or prevention of bronchospasm in appropriate patients. This bronchodilator mechanism differs from anti-inflammatory maintenance treatment. Recognising albuterol as a symptom-relieving medication helps identify requests that signal worsening control, such as a patient reporting a new need for increasingly frequent use. Those changes require pharmacist assessment rather than simply an early refill explanation.
Apply it
A patient requests an albuterol refill much sooner than usual and reports needing it repeatedly throughout the day. Record the change in use and bring it to the pharmacist because increased rescue use can signal deteriorating control.
Common pitfall: Rapid symptom relief does not establish that the underlying airway inflammation is controlled; a bronchodilator's immediate effect should not be confused with preventive anti-inflammatory action.
14.Why can albuterol cause tremor or palpitations?
Although albuterol targets beta-2 receptors to produce bronchodilation, adrenergic effects can also cause tremor, nervousness, tachycardia, or palpitations. These effects connect the drug's pharmacology to common symptom reports. Their occurrence does not prove an allergy, and their severity and associated symptoms matter. Capture when symptoms began, how the inhaler was used, and whether use has increased. Significant or persistent cardiovascular symptoms require pharmacist assessment rather than independent reassurance or a technician-directed dose change.
Apply it
A patient reports shaky hands and a racing heartbeat after using albuterol more often than usual. Document the symptoms and reported frequency, then obtain pharmacist review of the adverse effects and the increased need for treatment.
Common pitfall: Do not label every unpleasant effect as an allergy or assume that a recognised adverse effect is harmless regardless of its severity and circumstances.
15.When does worsening breathing after albuterol suggest paradoxical bronchospasm?
Albuterol inhalation products can cause paradoxical bronchospasm, in which airway narrowing worsens after administration instead of improving. This potentially life-threatening reaction differs from mild tremor or nervousness. The decisive cue is a temporal association between inhaler use and immediate worsening of breathing. The label directs discontinuation and alternative therapy when this occurs; a technician should promptly involve the pharmacist and follow urgent-response procedures rather than encourage repeated doses of the suspected product.
Apply it
A caller says each use of a newly opened albuterol inhaler immediately makes wheezing worse. Recognise the pattern as a serious adverse-reaction signal and obtain immediate pharmacist involvement instead of treating the complaint as routine technique coaching.
Common pitfall: Do not assume every failure to improve means too little bronchodilator was used; immediate deterioration after administration can indicate a reaction to the product itself.
16.Why does an amoxicillin prescription require allergy review?
Amoxicillin is a penicillin-class antibacterial used for susceptible bacterial infections. Its antibacterial action does not treat viral illness, and its class identity matters when reviewing a history of serious beta-lactam hypersensitivity. A report of anaphylaxis, facial swelling, or breathing difficulty has different significance from isolated nausea. Record the specific reaction and implicated drug rather than reducing all reports to an undifferentiated allergy label. The pharmacist determines the clinical significance and treatment implications.
Apply it
Before processing amoxicillin, a patient reports that penicillin once caused facial swelling and difficulty breathing. Preserve those reaction details and stop routine processing for pharmacist assessment rather than dismissing the history as ordinary stomach intolerance.
Common pitfall: A nonspecific 'upset stomach' history and a serious immediate hypersensitivity history require different interpretation; neither should be silently substituted for the patient's actual description.
DailyMed — AMOXIL Oral Suspension · PTCE Content Outline — Effective January 6, 2026
17.How does final suspension volume differ from water added?
A powder for oral suspension contributes to the final preparation volume, so the amount of water added is not generally identical to the final labelled volume. Product-specific reconstitution instructions establish the water quantity and resulting concentration. Select the exact product and bottle size before following those instructions. A dose calculation based on the final concentration does not independently establish the reconstitution procedure, and adding water equal to the final volume can produce an incorrectly diluted preparation.
Apply it
A bottle is labelled to yield 100 mL after reconstitution. Instead of adding 100 mL of water automatically, staff identify the exact amoxicillin product and follow its specified water quantity and mixing instructions before checking the final preparation.
Common pitfall: Do not infer water volume from final bottle volume; powder displacement and manufacturer-specific preparation instructions make that shortcut unreliable for achieving the labelled concentration.
18.Why must amoxicillin suspension be shaken before measuring?
A suspension contains dispersed drug particles that can settle during storage. Shaking redistributes those particles so a measured volume more closely represents the labelled concentration. The cited amoxicillin instructions also support using a calibrated oral dosing device. Shaking addresses concentration uniformity, while a calibrated device addresses volume accuracy; both are necessary. Neither a familiar household spoon nor precise volume measurement can compensate for a suspension that has not been adequately mixed.
Apply it
A caregiver carefully measures the prescribed volume but never shakes the amoxicillin bottle. Explain the need to redisperse the suspension and provide the labelled directions with a calibrated oral syringe for pharmacist-reviewed counselling.
Common pitfall: Accurate syringe markings do not guarantee an accurate dose when settled particles make the liquid concentration uneven; mixing and measuring solve different problems in administration.
19.When should the cited reconstituted Amoxil suspension be discarded?
The cited Amoxil oral suspension label directs discarding unused reconstituted suspension after 14 days. Refrigeration is preferable but not required for that product. Reconstitution starts a different stability period from the unopened powder's manufacturer expiration date. Record preparation information and apply the product-specific discard instruction. This interval should not be extended merely because the suspension looks normal or has been refrigerated, and it should not be generalised to every antibiotic suspension.
Apply it
An Amoxil suspension was reconstituted 16 days ago and kept refrigerated. Its appearance remains unchanged. Identify that the labelled 14-day interval has elapsed and keep it from further dispensing or use despite its normal appearance.
Common pitfall: Refrigeration does not automatically extend a labelled discard interval, and another antibiotic suspension may have a different storage requirement or usable period after preparation.
20.How do manufacturer expiration and in-use stability differ?
A manufacturer's expiration date applies under the product's specified conditions, including its relevant packaging state. Opening, reconstitution, or another manipulation can create an earlier in-use limit. For the cited Amoxil suspension, the 14-day post-reconstitution instruction becomes relevant even when the powder's printed expiration is much later. Determine both the original expiration and any preparation-dependent limit, then use the applicable earlier boundary. Normal colour or smell does not establish chemical potency or microbiological suitability.
Apply it
A powder bottle expires next year, but its suspension was prepared three weeks ago. Compare the preparation record with the label's post-reconstitution limit rather than approving it solely because the manufacturer expiration date has not passed.
Common pitfall: The longest visible date is not automatically the controlling date; preparation and opening can introduce an earlier limit that governs whether a product remains usable.
DailyMed — AMOXIL Oral Suspension · PTCE Content Outline — Effective January 6, 2026
21.What distinguishes a contraindication from an adverse effect?
A contraindication identifies a circumstance in which a medication should not be used because the risk is unacceptable under the label. An adverse effect is an undesirable response that can occur during use and may vary in severity. Nitrostat with sildenafil exemplifies a contraindicated combination; headache is a recognised nitrate adverse effect. The distinction determines how an alert is interpreted. A potentially dangerous combination cannot be treated as merely another expected symptom to monitor.
Apply it
A profile presents two issues: a previous nitrate-related headache and current sildenafil use. Recognise that the headache history describes an adverse effect, while sildenafil creates a labelled contraindication requiring assessment before Nitrostat is supplied.
Common pitfall: Do not use 'side effect,' 'allergy,' and 'contraindication' interchangeably; each describes a different relationship between the medication, the patient, and the associated risk.
Federal Requirements18.75%
23.How do federal controlled-substance schedules differ?
Federal schedules classify substances using factors including accepted medical use and abuse or dependence potential. Schedule I substances have no currently accepted medical use in treatment in the United States under federal scheduling criteria. Schedule II substances have accepted medical uses but high abuse potential, with severe dependence risk. Schedules III through V reflect progressively lower abuse potential relative to the preceding categories. Scheduling directs legal controls; it is not a ranking of ordinary therapeutic effectiveness.
Apply it
A learner assumes that any medication prescribed legally must be outside the highest-risk schedules. Use Schedule II to show that accepted medical use and high abuse potential can coexist, producing strict controls without eliminating legitimate prescribing.
Common pitfall: Do not equate Schedule II with 'no medical use'; that criterion distinguishes Schedule I under federal scheduling, while Schedule II includes medications with accepted uses.
24.Why cannot a Schedule II prescription be refilled?
Federal law prohibits refilling Schedule II prescriptions. A prescriber's notation requesting refills does not override that prohibition. Distinguish a refill from a separately issued prescription and from a partial fill, because these are different legal transactions with their own requirements. When the request is truly to refill a completed Schedule II prescription, the prohibition is decisive. Do not infer current transfer or partial-fill procedures solely from the refill rule or an older manual's examples.
Apply it
A completed Schedule II prescription shows 'two refills' in a handwritten field. Identify that the notation cannot authorise federal Schedule II refills and route the request for pharmacist resolution and any necessary new prescription.
Common pitfall: Multiple prescriptions or legally permitted partial fills are not the same as refills; treating these categories as interchangeable leads to incorrect federal-rule conclusions.
25.When do Schedule III and IV refill limits stop further dispensing?
Under the cited federal DEA guidance, Schedule III and IV prescriptions may be refilled no more than five times and not beyond six months after the prescription's issue date. Both limits apply, and the prescriber must have authorised the refill. A remaining authorised refill does not extend the six-month period, and an unexpired prescription does not create extra refills beyond the limit. State requirements and patient-specific concerns can impose additional restrictions on an otherwise federally eligible request.
Apply it
A Schedule IV prescription is seven months old and has only two recorded refills. Although fewer than five refills have occurred, identify the elapsed six-month boundary as preventing another refill under the cited federal rule.
Common pitfall: Do not count six months from the most recent dispensing date; the federal time limit is tied to the prescription's issue date, not refill activity.
DEA Pharmacist's Manual — 2022 Edition · DEA Practitioner's Manual — 2023 Edition
26.Which ordering records distinguish Schedule II inventory?
Ordering Schedule I or II controlled substances generally uses DEA Form 222 or the electronic Controlled Substance Ordering System, known as CSOS. Routine Schedule III through V purchases use invoice records rather than Form 222. The schedule therefore determines the ordering documentation pathway. Match the order, shipment, and receiving record so discrepancies can be investigated. Form 222 is an ordering document; it does not replace a patient's prescription or the records needed for dispensing.
Apply it
A purchaser prepares routine stock orders for Schedule II and Schedule IV medications. Route the Schedule II transaction through the applicable Form 222 or CSOS process and preserve invoice documentation for the Schedule IV purchase.
Common pitfall: DEA Form 222 is not the standard form for every controlled substance, and it does not authorise patient dispensing without an appropriate prescription.
27.When must a controlled-substance theft or significant loss be reported?
A DEA registrant must notify the appropriate DEA Field Division Office in writing within one business day after discovering a theft or significant loss of controlled substances. Separately, the registrant must submit a complete and accurate DEA Form 106 electronically through DEA’s Diversion Control Division secure network application within 45 calendar days after discovery. These are two distinct reporting obligations measured from discovery. Initial notification alerts DEA promptly; the detailed form allows time to investigate and accurately document the substances and quantities involved. An unfinished internal investigation does not suspend the initial notification requirement.
Apply it
A confirmed theft is discovered while the final inventory count is still being reconciled. Alert the responsible pharmacist or registrant immediately so written notification reaches the appropriate DEA field division within one business day. Assemble inventory records and reconcile the stolen quantities for a complete and accurate electronic Form 106 submission within 45 calendar days after discovery.
Common pitfall: Do not wait for the investigation to finish before providing initial written notification. The 45-day period runs from discovery, not from the initial notification, and uses calendar days rather than business days. Mailing a paper Form 106 does not satisfy the electronic submission requirement. Form 222 is an ordering document, not the theft-or-loss report.
DEA Diversion Control Division — Theft/Loss Reporting · Diversion Control Division | Civil Unrest/Looting Registration Guidance Documents Q&A · 2023-13085.pdf
28.How does controlled stock disposal differ from patient take-back?
A pharmacy's controlled-substance inventory and controlled medications surrendered by an ultimate user are different regulatory streams. Inventory disposal can involve transfer to an authorised reverse distributor or another permitted registrant procedure. Patient take-back requires an authorised collection arrangement rather than an ordinary stock return. Ownership, source, and collection authority determine the pathway before packaging or transfer occurs. Receiving a patient's returned bottle does not restore it to legitimate dispensing inventory or make every pharmacy an authorised collector.
Apply it
Staff find expired controlled stock while a patient separately asks to surrender unused tablets from home. Keep the two streams distinct and identify the pharmacy's authorised inventory-disposal and patient-collection arrangements before accepting or transferring either material.
Common pitfall: A reverse-distribution route for pharmacy inventory does not automatically authorise accepting ultimate-user medications through the same process or returning patient-held products to dispensing stock.
29.Which federal waste rule applies even to very small healthcare generators?
Healthcare facilities and reverse distributors must not dispose of hazardous waste pharmaceuticals into a sink, toilet, or other sewer drain. This federal sewering prohibition also applies to healthcare facilities that are very small quantity generators. A discarded pharmaceutical is hazardous waste if it meets an applicable hazardous-waste listing or exhibits ignitability, corrosivity, reactivity, or toxicity. Controlled-substance status addresses diversion and must be assessed separately. An inventory return that may receive credit does not, by itself, remove applicable hazardous-waste requirements.
Apply it
A pharmacy has unused cyclophosphamide stock classified as U058 hazardous waste for disposal. Even if the pharmacy is a very small quantity generator, do not pour it down a drain. Segregate it into the designated hazardous-pharmaceutical-waste pathway. An intact, usable surplus bottle accepted for an ordinary supplier return requires a separate return decision; its commercial return status cannot establish how hazardous waste may be discarded.
Common pitfall: Noncontrolled does not mean nonhazardous. Small waste quantities do not create an exemption from the sewer ban, and neither a general returns bin nor ordinary trash is an automatic destination for hazardous waste pharmaceuticals.
Frequent Questions about the Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine Final Rule | US EPA · DEA Pharmacist's Manual — 2022 Edition · PTCE Content Outline — Effective January 6, 2026
30.How can a REMS change prescription processing?
A Risk Evaluation and Mitigation Strategy is an FDA-required safety programme for certain medications when additional measures are necessary to ensure that benefits outweigh risks. Depending on the product, requirements can include education, certification, enrolment, monitoring, or dispensing restrictions. The operative requirement is the specific programme's current condition for dispensing, not the mere presence of a warning. A paid claim or valid prescription does not demonstrate that required REMS steps have been completed.
Apply it
A restricted medication's claim pays, but its programme requires confirmation of a dispensing authorisation. Hold release until the required programme condition is verified rather than treating insurance payment as proof that all safety requirements are satisfied.
Common pitfall: Do not assume every REMS uses the same enrolment or laboratory process; FDA programmes differ, and ordinary coverage approval does not substitute for programme compliance.
31.What distinguishes FDA recall Classes I, II, and III?
FDA recall classes describe the health hazard associated with a product problem. Class I involves a reasonable probability of serious adverse health consequences or death. Class II involves temporary or medically reversible consequences, or a remote probability of serious consequences. Class III involves a situation unlikely to cause adverse health consequences. Classification describes risk; the actual notice identifies affected products and required actions. A lower class does not make recalled units acceptable for routine continued distribution.
Apply it
A recall notice describes a reasonable probability that use could cause serious injury. Recognise the Class I criterion and promptly identify and isolate affected inventory according to the notice, without waiting for a patient to report harm.
Common pitfall: Recall classes are not controlled-substance schedules or product potency grades; they communicate the health-risk assessment associated with the recall and do not replace its instructions.
32.How should an affected recall lot be identified?
A recall notice may identify a particular product, strength, dosage form, package, lot, or expiration range. Compare all specified identifiers with physical inventory and relevant dispensing records. Lot-level matching prevents both continued distribution of affected units and unnecessary assumptions about unrelated batches. Once identified, segregate affected stock and follow the notice's return, communication, and documentation instructions. The recall class establishes risk, while the listed identifiers establish which units the action actually covers.
Apply it
Two bottles have the same product and strength, but only one lot appears in a recall notice. Isolate the matching bottle and check relevant records using that lot information rather than treating product name alone as the complete criterion.
Common pitfall: A shared NDC can cover multiple production lots; product identification alone cannot establish whether a particular bottle falls within a lot-specific recall notice.
FDA — Recalls and Shortages Branch · openFDA — Drug NDC Field Reference
33.When should a suspect prescription drug be quarantined under DSCSA?
DSCSA supply-chain protections require attention to suspect prescription products, including evidence suggesting counterfeiting, diversion, theft, or adulteration. A suspect product must be quarantined and investigated to determine whether it is illegitimate. Keep it from dispensing while the concern is unresolved and preserve transaction and product information. A product's familiar brand or apparently acceptable expiration date does not resolve suspicious provenance. A confirmed illegitimate product triggers additional notification obligations under the applicable FDA process.
Apply it
A delivered package has inconsistent identifying information and altered packaging compared with its transaction records. Segregate it from saleable stock and alert the pharmacist for the DSCSA investigation rather than dispensing it because the printed expiration remains current.
Common pitfall: Do not wait for proof of patient injury before isolating suspect stock; quarantine supports investigation before the product can enter the dispensing stream.
FDA — Pharmacists: Utilize DSCSA Requirements to Protect Your Patients
Patient Safety and Quality Assurance23.75%
34.What makes a medication high alert?
High-alert medications carry a heightened risk of significant harm when used in error. The designation does not mean errors necessarily happen more frequently with those medications. Insulin, anticoagulants, and other listed community medications warrant safeguards suited to the consequences of a wrong drug, dose, or patient. Identify the particular failure being prevented, such as concentration confusion, rather than adding an unspecified extra check. A high-alert classification strengthens the need for reliable systems throughout the workflow.
Apply it
A pharmacy introduces a second insulin concentration beside an existing product. Recognise that selecting the wrong concentration could cause substantial harm and support distinct storage and product-verification safeguards aimed specifically at that selection risk.
Common pitfall: Do not define high alert as 'most commonly prescribed' or 'most frequently miscounted'; the central feature is the severity of harm when an error occurs.
ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
35.How does Tall Man lettering reduce look-alike name confusion?
Tall Man lettering capitalises selected portions of similar drug names to draw attention to their differences. FDA's name-differentiation work uses this visual cue to reduce confusion between look-alike names. It supplements ingredient, strength, dosage-form, and order verification rather than replacing them. The discriminating task remains matching the full intended medication. Additional separation or alerts may be useful when products remain easy to confuse despite name differentiation, particularly when packages also look similar.
Apply it
Two similarly named medications appear next to each other in a selection menu. Use their differentiated lettering to inspect the distinguishing name segments, then compare the complete selected product with the original prescription before proceeding.
Common pitfall: Capitalisation is a visual warning, not proof of correct selection; a reader can still choose the wrong strength, formulation, or similarly named ingredient.
36.Why should doses use leading zeros and avoid trailing zeros?
A leading zero makes a fractional dose easier to recognise: write 0.5 mg rather than .5 mg. A trailing zero after a whole-number dose can create a tenfold error if the decimal point is missed: write 5 mg rather than 5.0 mg. These conventions reduce ambiguity before transcription or administration. The unit must remain explicit as well. Safe notation improves communication, but a clearly written dose still requires comparison with the original order and clinical review when indicated.
Apply it
A draft label contains '.5 mg' and a worksheet contains '5.0 mg.' Correct the communication to '0.5 mg' and '5 mg' while preserving the intended doses, then verify both against the authorised source orders.
Common pitfall: Adding a trailing zero does not make a medication dose safer or more precise; it can turn a missed decimal into a tenfold interpretation error.
ISMP List of Error-Prone Abbreviations, Symbols, and Dose Designations — 2024
37.Which abbreviations create avoidable unit errors?
ISMP identifies abbreviations such as U and IU as error prone because they can resemble numbers or other characters. Writing 'units' or 'international units' removes that ambiguity. Similar concerns apply when frequency abbreviations can be confused, so clear wording is preferable in patient-facing directions. The response to an unclear original order is clarification, not guessing a likely intended value. Standardisation is effective only when it preserves the verified meaning and removes an identifiable source of misreading.
Apply it
An order appears to read '10 U,' but the final character resembles a zero. Preserve the original for clarification and ensure the confirmed instruction is communicated with the word 'units' rather than carrying the ambiguous abbreviation forward.
Common pitfall: Do not resolve unclear handwriting by choosing the most familiar dose; replacing an abbreviation with clear wording is safe only after the intended instruction is established.
ISMP List of Error-Prone Abbreviations, Symbols, and Dose Designations — 2024
38.How do patient identifiers prevent wrong-patient dispensing?
A correctly prepared medication can still cause harm if linked to the wrong person. Compare independent identifiers, such as full name and date of birth, with the prescription and patient record at relevant handoffs. A surname alone, a remembered face, or a shared address may not distinguish family members or patients with similar names. The important check is agreement between the person, record, and intended prescription, rather than confirmation that a bag carries some plausible name.
Apply it
Two patients named Jordan Lee have prescriptions ready. Ask for and compare an additional identifier, such as date of birth, with the selected record and prescription before releasing either bag, even if one patient is familiar.
Common pitfall: A correct name on a bag does not establish the correct recipient when names overlap; recognition and routine familiarity can reinforce an initial selection mistake.
39.What can barcode verification confirm and miss?
Barcode verification can compare a scanned stock product with the product selected in the dispensing system. It helps intercept selection errors involving the wrong medication, strength, or package when the system is configured for those checks. It cannot establish that the original prescription was entered for the correct patient or that an entered dose is clinically appropriate. Automation checks a defined relationship. Its protection weakens when staff bypass alerts, scan a substitute container, or rely on incorrect upstream data.
Apply it
A stock bottle scans successfully, but the technician notices that the entered patient date of birth differs from the prescription. Stop the workflow: product agreement cannot resolve the separate wrong-patient entry discrepancy or justify releasing the medication.
Common pitfall: A successful scan is not an all-purpose safety approval; it may confirm consistency with an incorrectly selected record or incorrectly entered prescription.
40.How should an allergy history be made clinically useful?
An allergy record is more useful when it identifies the implicated drug, the reaction, and relevant timing rather than only stating 'allergic.' Immune-mediated reactions and predictable intolerance have different implications, although both deserve accurate documentation. For amoxicillin processing, a history of serious beta-lactam hypersensitivity is a specific safety concern. Record the patient's words without independently deleting an allergy entry or declaring a medication safe. The pharmacist interprets the history and determines the treatment implications.
Apply it
A patient says an old allergy entry refers to nausea, while a relative recalls breathing difficulty after a different antibiotic. Record the separate drugs and reactions accurately and ask the pharmacist to reconcile the history before amoxicillin processing continues.
Common pitfall: Do not automatically convert every intolerance into an allergy or remove a serious allergy warning because one part of the history sounds like a common adverse effect.
DailyMed — AMOXIL Oral Suspension · PTCE Content Outline — Effective January 6, 2026
41.When does a medication concern require pharmacist intervention?
The PTCE outline identifies interactions, allergies, adverse events, therapeutic substitution, misuse, adherence, and OTC recommendations as issues requiring pharmacist intervention. A useful escalation includes the medication, relevant patient report, conflicting information, and the precise unresolved decision. For example, Nitrostat with sildenafil presents a labelled contraindication, not simply a missing administrative field. A technician can detect and communicate the problem while avoiding an independent clinical override, replacement recommendation, or change to the prescribed regimen.
Apply it
A patient asks staff to replace a prescribed medication with an OTC product because of a new symptom. Gather the current medication and symptom details, then involve the pharmacist to assess the symptom and select any appropriate alternative.
Common pitfall: A familiar product or common symptom does not make therapeutic substitution an administrative task; the decision depends on clinical appropriateness and patient-specific safety information.
PTCE Content Outline — Effective January 6, 2026 · DailyMed — NITROSTAT
42.Why should an intercepted near miss be reported?
A near miss exposes a failure pathway even when interception prevents the error from reaching the patient. Reporting captures where the process failed and which safeguard succeeded, allowing improvement before a similar event causes harm. Useful documentation includes the intended task, actual selection or entry, detection point, and contributing conditions. Reporting should support learning rather than end with praise for the person who caught it. Repeated interceptions may reveal a persistent system weakness that has not yet produced injury.
Apply it
A technician catches a wrong-strength bottle before counting begins. Record the near miss, including the similar packaging and adjacent shelf placement, so the team can address the recurring selection risk instead of merely returning the bottle.
Common pitfall: No patient harm does not mean no safety information exists; excluding intercepted errors hides the conditions that may cause a future event when interception fails.
PSNet — Errors and Near Misses: What Health Care Could Learn From Aviation
43.How does root-cause analysis move beyond individual blame?
Root-cause analysis examines how system conditions contributed to an event and identifies changes intended to reduce recurrence. Staffing, workflow, software design, storage, communication, and barriers can all matter. An explanation such as 'someone was careless' stops analysis before those contributors are examined. Corrective actions should address the identified mechanism and be evaluated for effectiveness. Education may be useful, but relying only on reminders is weak when the underlying process continues to make the same error easy.
Apply it
Several wrong-strength selections occur despite repeated reminders. Review shelf arrangement, packaging similarity, screen defaults, interruptions, and scanning practices, then select a corrective change that directly addresses the observed selection pathway and monitor whether events decline.
Common pitfall: Identifying the last person who touched the prescription is not the same as identifying the conditions that allowed the error to occur and escape earlier barriers.
44.How should a suspected medication product defect be documented?
FDA product-problem reporting supports investigation of quality concerns such as unexpected contamination, packaging defects, or abnormal product appearance. Preserve the product name, strength, manufacturer, lot number, expiration, and a clear description of the defect when available. These identifiers can connect separate reports to a particular batch or package. A suspected quality problem can be important without a patient injury. Isolate affected stock through the pharmacy's process and support appropriate MedWatch reporting rather than discarding the evidence immediately.
Apply it
An unopened bottle contains visibly damaged tablets, and a second bottle from the same lot appears similar. Segregate the bottles and record their lot, expiration, manufacturer, and observed defects for pharmacist review and possible FDA product-problem reporting.
Common pitfall: Do not omit lot information or discard all packaging before documentation; those details may be essential for distinguishing a batch problem from an isolated handling event.
45.How should a dose or route discrepancy be resolved?
A discrepancy between the source prescription and the entered drug, dose, quantity, patient, or route is a potential prescription-processing error. Compare the original instruction, selected product, calculation, and draft label to locate the mismatch. Do not silently replace an unusual instruction with a familiar regimen, because familiarity does not establish prescriber intent. Correct a verified transcription error through the authorised workflow; obtain clarification and pharmacist assessment when the intended clinical instruction itself remains uncertain.
Apply it
An original order specifies a sublingual tablet, but the entered directions instruct swallowing. Stop the label and compare the source with the product before correction and verification, preserving the distinction between an entry error and an unclear prescription.
Common pitfall: A mathematically correct quantity can accompany the wrong route or patient; checking arithmetic alone does not establish that the prescription was processed correctly overall.
PTCE Content Outline — Effective January 6, 2026 · DailyMed — NITROSTAT
46.When is soap-and-water handwashing necessary?
CDC guidance calls for washing with soap and water when hands are visibly soiled. Alcohol-based hand sanitiser is preferred in many other healthcare situations when hands are not visibly soiled, subject to applicable clinical circumstances. The visible-soil cue matters because routine sanitiser use should not replace removal of dirt or material from contaminated hands. Hand hygiene also complements, rather than replaces, cleaning of shared equipment and work surfaces under the applicable pharmacy procedure.
Apply it
After cleaning a spill, a technician sees visible residue on the hands. Wash with soap and water before returning to medication handling rather than applying sanitiser over the residue and immediately resuming work at the counting station.
Common pitfall: A readily available sanitiser dispenser does not make sanitiser the right response to visibly dirty hands, and clean hands do not establish that equipment is clean.
CDC — Clinical Safety: Hand Hygiene for Healthcare Workers · PTCE Content Outline — Effective January 6, 2026
47.Why do gloves not replace hand hygiene?
Gloves provide a barrier for selected tasks but can become contaminated and can transfer organisms between surfaces or patients. CDC guidance requires hand hygiene at appropriate moments, including after glove removal. Gloves must also be changed when moving between tasks in ways that would carry contamination forward. The decision depends on the task transition and contamination risk, not merely whether a glove looks intact. A single pair worn across several activities does not create a continuously clean working state.
Apply it
A worker finishes a contaminated cleaning task while gloved and then reaches toward medication equipment. Remove the contaminated gloves, perform hand hygiene, and use task-appropriate protection before beginning the next activity instead of continuing with the same pair.
Common pitfall: Glove integrity does not establish glove cleanliness; an unbroken glove can still carry contamination from a previous task directly onto a clean surface.
Order Entry and Processing22.50%
22.How do return to stock, credit return, and reverse distribution differ?
Return to stock restores eligible medication to dispensable inventory under applicable law and pharmacy procedure. For an uncollected prescription that remained in pharmacy custody, verify identity, storage history, packaging integrity, expiration or in-use limit, and recall status before an authorised return. Credit return sends eligible pharmacy-owned stock to a supplier or manufacturer under its return policy; obtain the required authorisation and reconcile shipped quantities with credit received. Reverse distribution provides a regulated route for appropriate inventory returns, including expired controlled stock transferred to a DEA-registered reverse distributor. Financial credit does not establish dispensability. Document product identifiers, quantity, source, condition, disposition, and applicable transfer records.
Apply it
Compare three pharmacy-owned items: an intact, uncollected prescription may return to stock after all checks and required approval; an unopened surplus bottle accepted under the supplier's policy follows its authorised credit-return procedure; expired Schedule II stock stays segregated and can follow an authorised reverse-distribution route using Form 222 or CSOS records. Record lot and expiration where applicable and reconcile each removal from inventory.
Common pitfall: These pathways are not interchangeable. Patient-held medications do not become ordinary return-to-stock inventory, recalled units follow the recall notice, and hazardous waste remains subject to applicable EPA requirements even when a return may generate credit.
PTCE Content Outline — Effective January 6, 2026 · DEA Pharmacist's Manual — 2022 Edition · FDA — Recalls and Shortages Branch · Frequent Questions about the Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine Final Rule | US EPA
48.How is a liquid dose converted from milligrams to millilitres?
Divide the prescribed dose by the product concentration expressed in compatible units. For a concentration of 250 mg per 5 mL, the product contains 50 mg/mL. A verified 375 mg dose therefore requires 7.5 mL. Writing units through the calculation helps detect an inverted ratio: milligrams should cancel, leaving millilitres. Confirm the actual product strength before calculating, because the same ingredient can be supplied at more than one concentration.
Apply it
A verified order calls for 300 mg per dose, and the selected suspension contains 200 mg per 5 mL. Calculate 300 × 5 ÷ 200 = 7.5 mL per dose, then compare the result with the draft label.
Common pitfall: Do not copy a volume from a previous prescription without checking concentration; the same milligram dose can require a different volume when the product strength changes.
49.How is tablet quantity calculated for a fixed course?
Calculate units per dose, multiply by doses per day, and then multiply by treatment days. If a verified order requires two tablets per dose, three doses daily, for seven days, the total is 2 × 3 × 7 = 42 tablets. Keep tablet strength separate from tablet count; a milligram dose may require conversion before quantity is known. The arithmetic establishes the required amount under the supplied instructions, not whether the clinical regimen is appropriate.
Apply it
A verified order requires 500 mg twice daily for six days using 250 mg tablets. Each dose needs two tablets, so prepare a calculated quantity of 2 × 2 × 6 = 24 tablets for verification.
Common pitfall: Counting one tablet per administration without comparing tablet strength with the prescribed dose can produce the correct frequency but only half the required total quantity.
50.How is days supply determined from fixed daily use?
For a constant regimen, divide the total quantity dispensed by the quantity used each day. A supply of 90 tablets taken as one tablet three times daily lasts 30 days. For liquids, both numerator and denominator should use volume; for tablets, both should use tablet units. Do not substitute the number of administration times for the number of units consumed. Variable or as-needed instructions require additional assumptions rather than an invented fixed daily use.
Apply it
A verified liquid instruction is 5 mL twice daily, and 150 mL will be dispensed. Daily use is 10 mL, so the calculated supply is 150 ÷ 10 = 15 days, assuming the stated fixed regimen.
Common pitfall: Twice daily does not necessarily mean two tablets or two millilitres daily; multiply the amount at each administration by the number of administrations first.
51.How should a tapering regimen be totalled?
A taper changes daily use, so calculate each phase separately and add the phase quantities. For example, four tablets daily for two days, then two daily for three days, then one daily for two days requires 8 + 6 + 2 = 16 tablets over seven days. Averaging without carefully accounting for phase lengths can produce errors. Preserve both the changing instructions and the total duration; the final phase alone does not describe the full course.
Apply it
A hypothetical verified course uses three tablets daily for two days, two daily for two days, then one daily for three days. Calculate 6 + 4 + 3 = 13 tablets over a seven-day course before checking the entered quantity.
Common pitfall: Do not multiply the first day's tablet count by the entire course or calculate days supply using only the final daily dose in a taper.
52.How do milligrams per kilogram per day differ from per-dose instructions?
A dose expressed in mg/kg/day establishes the total daily amount, which must then be divided among the stated administrations. A dose expressed in mg/kg/dose establishes each administration directly. For a hypothetical verified 20 mg/kg/day order in a 15 kg patient, the daily total is 300 mg; dividing it into three equal doses gives 100 mg per dose. The words 'per day' and 'per dose' are decisive and must remain visible through the calculation.
Apply it
A verified exercise specifies 24 mg/kg/day for an 18 kg patient in three equal doses. Calculate 432 mg daily and then 144 mg per dose, rather than administering the entire calculated daily amount at each administration.
Common pitfall: Multiplying by body weight is only the first step for a daily-total instruction; omitting the division across administrations can multiply the intended daily exposure.
53.What does percent weight-in-volume concentration mean?
Percent weight in volume, written % w/v, expresses grams of solute per 100 mL of final solution. A 2% w/v solution contains 2 g per 100 mL, equivalent to 20 mg/mL. The denominator is final preparation volume, not the amount of solvent initially added. Identify the percentage basis before calculating because weight-in-weight and volume-in-volume percentages describe different relationships. Unit conversion makes the result usable for dose or preparation calculations without changing the underlying concentration.
Apply it
A calculation exercise asks for the solute in 250 mL of a 0.4% w/v solution. Use 0.4 g per 100 mL to obtain 1 g in the final 250 mL volume, then verify the unit conversion.
Common pitfall: Do not interpret every percentage as milligrams per millilitre directly; 1% w/v equals 10 mg/mL after converting grams and accounting for the 100 mL denominator.
54.How does the dilution equation preserve drug amount?
For a compatible dilution with no drug loss, C1V1 = C2V2 expresses conservation of solute. Concentrations must use matching units, and V2 is the final volume after dilution. To prepare 100 mL of a 2% solution from a 10% stock, use 20 mL of stock and add the appropriate diluent to a final volume of 100 mL. The calculation alone does not establish diluent compatibility, stability, sterility, or an authorised preparation procedure.
Apply it
An approved hypothetical worksheet requires 120 mL at 5 mg/mL from a 20 mg/mL stock. Calculate V1 = 5 × 120 ÷ 20 = 30 mL stock, with the approved diluent added to a final 120 mL.
Common pitfall: Final volume is not automatically the volume of diluent to add; adding the full target volume of diluent to stock produces an excessive total volume.
55.How is an infusion rate calculated in millilitres per hour?
Divide the verified infusion volume by the infusion duration expressed in hours. A 250 mL volume over two hours corresponds to 125 mL/hour. When duration is given in minutes, convert to hours before division or include the conversion factor explicitly. This calculates a volumetric rate, not a drug dose rate such as mg/hour. Clinical suitability, device programming, concentration, and administration requirements remain separate checks under the applicable verified order and workflow.
Apply it
A hypothetical verified exercise specifies 180 mL over 90 minutes. Convert 90 minutes to 1.5 hours, then calculate 180 ÷ 1.5 = 120 mL/hour and compare the result with the proposed worksheet entry.
Common pitfall: Dividing millilitres by minutes produces mL/minute, not mL/hour; an unchanged numerical answer with the wrong time unit can create a sixtyfold discrepancy.
56.How are Celsius and Fahrenheit temperatures converted?
Use °F = (°C × 9/5) + 32 or °C = (°F − 32) × 5/9. Apply the subtraction or addition at the correct stage rather than treating the scales as a simple ratio. For example, 5°C equals 41°F. Conversion establishes equivalence between readings, but it does not establish a medication's acceptable storage range. Compare the converted value with the actual product's labelled requirements and assess any excursion through the appropriate process.
Apply it
A storage worksheet records 46.4°F while the product information uses Celsius. Calculate (46.4 − 32) × 5/9 = 8°C, then compare that value with the specific product's authorised storage conditions before determining acceptability.
Common pitfall: A numerically correct conversion does not prove acceptable storage; the product's labelled range and any excursion history must still be evaluated before stock is released.
57.How should common frequency codes become clear directions?
Common prescription codes such as b.i.d. and t.i.d. represent twice daily and three times daily. Translate the verified meaning into clear patient-facing directions while preserving the prescribed amount, route, and duration. Frequency alone does not establish a precise clock schedule or an interval such as every eight hours unless the order specifies it. Ambiguous or error-prone abbreviations require clarification rather than a confident guess. The finished directions should communicate the actual authorised instruction.
Apply it
A verified instruction reads 'one tablet PO b.i.d. for five days.' Translate it as 'Take one tablet by mouth twice daily for five days,' then calculate ten tablets without adding an unsupported clock-time schedule.
Common pitfall: Three times daily and every eight hours are not automatically identical instructions; do not introduce a precise interval that the verified order does not establish.
PTCE Content Outline — Effective January 6, 2026 · ISMP List of Error-Prone Abbreviations, Symbols, and Dose Designations — 2024
58.Which device supports accurate small-volume oral dosing?
A calibrated oral syringe measures liquid medication in marked volumes and is appropriate for many small oral doses. Match its capacity and graduations to the prescribed volume so the dose can be measured clearly. The cited amoxicillin instructions support calibrated dosing rather than household spoon estimation. Device selection complements concentration verification and suspension shaking. An oral dosing device should also remain clearly distinguished from equipment intended for injection so that the administration route is not confused.
Apply it
A prescription requires 2.5 mL of an oral suspension per dose. Select an oral syringe with clear markings that allow that volume to be measured, and verify that the caregiver receives the correct volume-based directions for the dispensed concentration.
Common pitfall: A kitchen teaspoon is not a reliably calibrated medication device, and a suitable syringe does not correct an incorrectly calculated dose or a misidentified product concentration.
DailyMed — Amoxicillin for Suspension · PTCE Content Outline — Effective January 6, 2026
59.What do the three NDC segments identify?
A National Drug Code contains labeler, product, and package segments. The labeler segment identifies the assigned labeler; the product segment identifies a particular product configuration, including features such as strength and dosage form; and the package segment identifies package size and type. NDC comparison therefore supports product and package selection. An NDC does not identify an individual production batch or establish an expiration date. Those require the actual lot and expiration information associated with the physical product.
Apply it
Two stock entries share labeler and product segments but differ in their package segment. Investigate package size or type before receiving the shipment or selecting a billing entry, rather than assuming the difference identifies another production lot.
Common pitfall: Do not use an NDC as a substitute for a lot number; multiple manufacturing lots can carry the same NDC and have different expiration information.
60.How do lot numbers and expiration dates support inventory decisions?
A lot number links a unit to a production batch, while an expiration date identifies its labelled time limit under specified conditions. These fields answer different questions: lot information supports tracing defects or recalls, and expiration supports time-based inventory control. Neither field replaces product identification. Compare all relevant identifiers when receiving, dispensing, rotating, or quarantining stock. A product with a current expiration may still be recalled, and an unaffected lot may still be unsuitable because it has expired.
Apply it
A bottle has a future expiration but belongs to a recalled lot, while another bottle is outside the recall but already expired. Remove both from dispensable stock for their different reasons and document the applicable identifiers accurately.
Common pitfall: A future expiration does not override a recall, and absence from a recall does not override expiration or another condition that makes stock nondispensable.
PTCE Content Outline — Effective January 6, 2026 · FDA — Recalls and Shortages Branch
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the January 6, 2026 outline as the complete scope, including topics beyond this selective guide.
- Learn ingredient–brand–class–indication relationships, then distinguish exact duplication, class overlap, contraindications, adverse effects, and formulation-specific handling.
- Separate federal refill eligibility, inventory ordering, theft notification, disposal authority, REMS completion, recall identification, and DSCSA quarantine decisions.
- Connect each safety safeguard to the failure it prevents: wrong patient, wrong product, tenfold notation error, unrecognised interaction, or contamination transfer.
- Show units in every calculation and distinguish daily dose from individual dose, stock volume from final volume, and product identity from batch identity.
- Extend inventory study to dispensable returns, nondispensable stock, expired products, credit returns, return to stock, and reverse distribution under the applicable procedures.
A practical preparation plan
1. Map the current outline
Create a study record for all four official domains and their knowledge areas. Allocate initial effort approximately by the published weights, then increase practice where explanations reveal a specific weakness.
2. Build medication comparison sheets
For each medication, connect brand, generic, class, indication, major warning, dosage form, administration, and storage. Compare similar products directly so a shared class never substitutes for ingredient or formulation verification.
3. Separate legal decision pathways
Practise refill, ordering, theft, disposal, REMS, recall, and suspect-product cases separately. State the federal criterion that determines each answer, and identify where state law or current programme requirements add conditions.
4. Calculate before viewing choices
Write the given quantity, target unit, conversion factors, and assumptions. Check the result against the original order and product concentration before comparing it with the answer options.
5. Explain every competing answer
Complete the 20 drills and explain why each alternative fails. Classify mistakes as knowledge gaps, missed discriminating cues, unit errors, or workflow errors, then revisit the matching concept.
6. Close scope gaps deliberately
Use the complete official outline to add medications, waste requirements, transfers, restricted programmes, administration equipment, and inventory-return procedures not developed fully here. Use the flashcards for spaced recall rather than treating repeated recognition as mastery.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Certified Pharmacy Technician (CPhT) — PTCB
- PTCE Content Outline — Effective January 6, 2026
- NHA Certified Pharmacy Technician (CPhT): Test Plan for the ExCPT Exam
- DailyMed — LIPITOR
- DailyMed — Metformin Hydrochloride Extended-Release Tablets
- DailyMed — Albuterol Sulfate HFA
- DailyMed — AMOXIL Oral Suspension
- DailyMed — Amoxicillin for Suspension
- DailyMed — NITROSTAT
- DEA Pharmacist's Manual — 2022 Edition
- DEA Diversion Control Division — Theft/Loss Reporting
- FDA — Recalls and Shortages Branch
- FDA — Pharmacists: Utilize DSCSA Requirements to Protect Your Patients
- FDA — Frequently Asked Questions About REMS
- ISMP List of Error-Prone Abbreviations, Symbols, and Dose Designations — 2024
- FDA Name Differentiation Project
- PSNet — Errors and Near Misses: What Health Care Could Learn From Aviation
- ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
- PSNet — Root Cause Analysis
- CDC — Clinical Safety: Hand Hygiene for Healthcare Workers
- FDA — Product Problems
- openFDA — Drug NDC Field Reference
- DailyMed — ZOLOFT
- FDA — Depression Medicines
- DEA Practitioner's Manual — 2023 Edition
- Grapefruit Juice and Some Drugs Don't Mix | FDA
- U.S.C. Title 21 - FOOD AND DRUGS
- Frequent Questions about the Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine Final Rule | US EPA
- Diversion Control Division | Civil Unrest/Looting Registration Guidance Documents Q&A
- 2023-13085.pdf
- What's in a REMS? | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.